Landovitz R, Scott H, Deeks S
Nat Rev Microbiol. 2023; 21(10):657-670.
PMID: 37344551
DOI: 10.1038/s41579-023-00914-1.
Podrazil M, Taborska P, Stakheev D, Rataj M, Lastovicka J, Vlachova A
Front Immunol. 2022; 13:892277.
PMID: 35669765
PMC: 9163958.
DOI: 10.3389/fimmu.2022.892277.
Costiniuk C, Singer J, Langlois M, Kulic I, Needham J, Burchell A
BMJ Open. 2021; 11(12):e054208.
PMID: 34916326
PMC: 8678543.
DOI: 10.1136/bmjopen-2021-054208.
Taborska P, Lastovicka J, Stakheev D, Strizova Z, Bartunkova J, Smrz D
Immun Inflamm Dis. 2021; 9(4):1452-1467.
PMID: 34314576
PMC: 8427053.
DOI: 10.1002/iid3.496.
Peluso M, Thanh C, Prator C, Hogan L, Arechiga V, Stephenson S
J Virus Erad. 2020; 6(1):19-26.
PMID: 32175087
PMC: 7043898.
Cost-Effectiveness of Peer- Versus Venue-Based Approaches for Detecting Undiagnosed HIV Among Heterosexuals in High-Risk New York City Neighborhoods.
Stevens E, Nucifora K, Zhou Q, Braithwaite R, Cleland C, Ritchie A
J Acquir Immune Defic Syndr. 2017; 77(2):183-192.
PMID: 29135654
PMC: 5762425.
DOI: 10.1097/QAI.0000000000001578.
Tackling HIV and AIDS: contributions by non-human primate models.
Van Rompay K
Lab Anim (NY). 2017; 46(6):259-270.
PMID: 28530684
DOI: 10.1038/laban.1279.
Immunologic profiles distinguish aviremic HIV-infected adults.
Ramirez C, Sinclair E, Epling L, Lee S, Jain V, Hsue P
AIDS. 2016; 30(10):1553-62.
PMID: 26854811
PMC: 5679214.
DOI: 10.1097/QAD.0000000000001049.
Viremic HIV Controllers Exhibit High Plasmacytoid Dendritic Cell-Reactive Opsonophagocytic IgG Antibody Responses against HIV-1 p24 Associated with Greater Antibody Isotype Diversification.
Tjiam M, Taylor J, Morshidi M, Sariputra L, Burrows S, Martin J
J Immunol. 2015; 194(11):5320-8.
PMID: 25911748
PMC: 4492937.
DOI: 10.4049/jimmunol.1402918.
HIV Replication at Low Copy Number and its Correlation with the HIV Reservoir: A Clinical Perspective.
Sarmati L, DEttorre G, Parisi S, Andreoni M
Curr HIV Res. 2015; 13(3):250-7.
PMID: 25845389
PMC: 4460281.
DOI: 10.2174/1570162x13666150407142539.
HIV Drug Resistance Profiles and Clinical Outcomes in Patients with Viremia Maintained at Very Low Levels.
Jordan M, Winsett J, Tiro A, Bau V, Berbara R, Rowley C
World J AIDS. 2015; 3(2):71-78.
PMID: 25664219
PMC: 4319662.
DOI: 10.4236/wja.2013.32010.
Estimating HIV-1 fitness characteristics from cross-sectional genotype data.
Gopalakrishnan S, Montazeri H, Menz S, Beerenwinkel N, Huisinga W
PLoS Comput Biol. 2014; 10(11):e1003886.
PMID: 25375675
PMC: 4222584.
DOI: 10.1371/journal.pcbi.1003886.
Emergence of drug resistance in human immunodeficiency virus type 1 infected patients from pune, India, at the end of 12 months of first line antiretroviral therapy initiation.
Patil R, Gupta R, Sen S, Tripathy S, Chaturbhuj D, Hingankar N
ISRN AIDS. 2014; 2014:674906.
PMID: 25006528
PMC: 4003797.
DOI: 10.1155/2014/674906.
Molecular epidemiology of human immunodeficiency virus type 1 in Guangdong province of southern China.
Chen S, Cai W, He J, Vidal N, Lai C, Guo W
PLoS One. 2012; 7(11):e48747.
PMID: 23144953
PMC: 3492446.
DOI: 10.1371/journal.pone.0048747.
Predicted HIV-1 coreceptor usage among Kenya patients shows a high tendency for subtype d to be cxcr4 tropic.
Wambui V, Kiptoo M, Kinyua J, Odera I, Muge E, Muiruri P
AIDS Res Ther. 2012; 9(1):22.
PMID: 22838398
PMC: 3527298.
DOI: 10.1186/1742-6405-9-22.
Prolonged tenofovir treatment of macaques infected with K65R reverse transcriptase mutants of SIV results in the development of antiviral immune responses that control virus replication after drug withdrawal.
Van Rompay K, Trott K, Jayashankar K, Geng Y, LaBranche C, Johnson J
Retrovirology. 2012; 9:57.
PMID: 22805180
PMC: 3419085.
DOI: 10.1186/1742-4690-9-57.
Control of M184V HIV-1 mutants by CD8 T-cell responses.
Vollbrecht T, Eberle J, Roider J, Buhler S, Stirner R, Henrich N
Med Microbiol Immunol. 2011; 201(2):201-11.
PMID: 22200907
DOI: 10.1007/s00430-011-0222-1.
A Multicenter, Open Labeled, Randomized, Phase III Study Comparing Lopinavir/Ritonavir Plus Atazanavir to Lopinavir/Ritonavir Plus Zidovudine and Lamivudine in Naive HIV-1-Infected Patients: 48-Week Analysis of the LORAN Trial.
Ulbricht K, Behrens G, Stoll M, Salzberger B, Jessen H, Jessen A
Open AIDS J. 2011; 5:44-50.
PMID: 21643422
PMC: 3103898.
DOI: 10.2174/1874613601105010044.
CD4+ T cells from HIV-1-infected patients recognize wild-type and mutant human immunodeficiency virus-1 protease epitopes.
Muller N, Alencar R, Jamal L, Hammer J, Sidney J, Sette A
Clin Exp Immunol. 2011; 164(1):90-9.
PMID: 21352200
PMC: 3074221.
DOI: 10.1111/j.1365-2249.2011.04319.x.
A low T regulatory cell response may contribute to both viral control and generalized immune activation in HIV controllers.
Hunt P, Landay A, Sinclair E, Martinson J, Hatano H, Emu B
PLoS One. 2011; 6(1):e15924.
PMID: 21305005
PMC: 3031543.
DOI: 10.1371/journal.pone.0015924.